The colon cancer BRAFF mutation study is one of the first to be initiated under the FDA’s Project FrontRunner.

Experts believe that pharma will continue as normal due to the scientific justification of running diverse clinical trials.

In partnership with global institutions, IIT Guwahati researchers have developed an adaptive multi-stage trial method.

Medical Devices conference, held in Munich, Germany on 28-29 January, was filled with sessions that dug into the minutiae of ...

A study from the University of Birmingham has indicated that digoxin could be used to treat senior individuals with heart ...

Paradigm Biopharmaceuticals has selected Advanced Clinical as the CRO to support its Phase III trial, PARA_OA_012, focused on ...

According to leading data and analytics company GlobalData’s Clinical Trials Database, over the past 20 years trial activity ...

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

MindMed has dosed the first subject in the Phase III Panorama study of MM120 ODT for the treatment of generalised anxiety ...

MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...

Kashiv Biosciences has reported that a trial of its 125mg/mL pre-filled syringe injection, KSHB002, has achieved its primary ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.